相关实验视频
Updated: May 6, 2026

06:25
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
Published on: June 14, 2021
5.2K
重新使用科尔福辛达洛帕特治疗MYC驱动的高度血清性卵巢癌
Matthew J Knarr1, Jamie Moon2, Priyanka Rawat1
1Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Science signaling
|November 19, 2024
概括
科尔福辛达罗帕特是一种福斯科林衍生物,在治疗高度血清性卵巢癌 (HGSOC) 中表现有前途. 它有效地减少了瘤生长,并在临床前模型中提高了化疗疗效,为这种致命的癌症提供了潜在的新疗法策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 高度血清性卵巢癌 (HGSOC) 存在重大挑战,原因是生存率低,缺乏早期检测,治疗选择有限.
- 福斯科林表现出抗癌性质,但体内适用性较差.
- 科尔福辛达罗帕特是一种水溶性福斯科林衍生物,与其作用机制相同,并已被批准用于急性心力衰竭.
研究的目的:
- 为了评估colforsin daropate对高度血清性卵巢癌 (HGSOC) 的治疗潜力.
- 在临床前的HGSOC模型中研究colforsin daropate的疗效和安全性.
主要方法:
- 在试验室中评估了对HGSOC细胞周期,细胞亡和入侵的科尔福辛达罗帕特的作用.
- 在正常的卵巢和输卵管细胞中评估了细胞毒性.
- 在皮下和腹腔内异位移植模型中确定体内疗效,包括与西斯的联合治疗.
- 研究了c-MYC在调解抗瘤效应中的作用.
主要成果:
- 科尔福辛达罗帕特诱导HGSOC细胞的细胞周期停止和细胞亡,对正常细胞的毒性最小.
- 它在体外抑制了HGSOC细胞的入侵.
- 在体内,colforsin daropate降低了瘤生长,与西斯普拉丁协同作用,并改善了生存率.
- 抗瘤效应部分归因于c-MYC水平和活性降低.
结论:
- 科尔福辛达洛帕特显示出作为HGSOC治疗的显著临床前疗效.
- 它表现出有利的安全性,不影响正常细胞.
- 科尔福辛达罗帕特作为一种新型治疗剂具有前景,有可能增强传统的卵巢癌治疗方法.
相关概念视频
Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703

